The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review
Over 50% of individuals with esophageal cancer (EC) present with advanced stages of the disease; therefore, their outcome following surgery alone is poor, with only 25%–36% being alive 5 years post-surgery. Based on the evidence that the CROSS and NEOCRTEC5010 trials provided, neoadjuvant chemoradio...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.890688/full |
| _version_ | 1818521823492440064 |
|---|---|
| author | Dan Han Dan Han Baosheng Li Qian Zhao Hongfu Sun Jinling Dong Shaoyu Hao Shaoyu Hao Wei Huang |
| author_facet | Dan Han Dan Han Baosheng Li Qian Zhao Hongfu Sun Jinling Dong Shaoyu Hao Shaoyu Hao Wei Huang |
| author_sort | Dan Han |
| collection | DOAJ |
| description | Over 50% of individuals with esophageal cancer (EC) present with advanced stages of the disease; therefore, their outcome following surgery alone is poor, with only 25%–36% being alive 5 years post-surgery. Based on the evidence that the CROSS and NEOCRTEC5010 trials provided, neoadjuvant chemoradiotherapy (nCRT) is now the standard therapy for patients with locally advanced EC. However, there are still many concerning clinical questions that remain controversial such as radiation dose, appropriate patient selection, the design of the radiation field, the time interval between chemoradiotherapy (CRT) and surgery, and esophageal retention. With immune checkpoint inhibitors (ICIs) rapidly becoming a mainstay of cancer therapy, along with radiation, chemotherapy, and surgery, the combination mode of immunotherapy is also becoming a hot topic of discussion. Here, we try to provide constructive suggestions to answer the perplexing problems and clinical concerns for the progress of nCRT for EC in the future. |
| first_indexed | 2024-12-11T01:56:30Z |
| format | Article |
| id | doaj.art-2b3fd8a22d2c469fa95a9791aa14e62e |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-11T01:56:30Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-2b3fd8a22d2c469fa95a9791aa14e62e2022-12-22T01:24:37ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-07-011210.3389/fonc.2022.890688890688The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A ReviewDan Han0Dan Han1Baosheng Li2Qian Zhao3Hongfu Sun4Jinling Dong5Shaoyu Hao6Shaoyu Hao7Wei Huang8Shandong University Cancer Center, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaShandong University Cancer Center, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaShandong University Cancer Center, Jinan, ChinaDepartment of Thoracic Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaOver 50% of individuals with esophageal cancer (EC) present with advanced stages of the disease; therefore, their outcome following surgery alone is poor, with only 25%–36% being alive 5 years post-surgery. Based on the evidence that the CROSS and NEOCRTEC5010 trials provided, neoadjuvant chemoradiotherapy (nCRT) is now the standard therapy for patients with locally advanced EC. However, there are still many concerning clinical questions that remain controversial such as radiation dose, appropriate patient selection, the design of the radiation field, the time interval between chemoradiotherapy (CRT) and surgery, and esophageal retention. With immune checkpoint inhibitors (ICIs) rapidly becoming a mainstay of cancer therapy, along with radiation, chemotherapy, and surgery, the combination mode of immunotherapy is also becoming a hot topic of discussion. Here, we try to provide constructive suggestions to answer the perplexing problems and clinical concerns for the progress of nCRT for EC in the future.https://www.frontiersin.org/articles/10.3389/fonc.2022.890688/fullesophageal cancerneoadjuvant chemoradiotherapyneoadjuvant immunotherapypathological complete remission (pCR)target volume delineation |
| spellingShingle | Dan Han Dan Han Baosheng Li Qian Zhao Hongfu Sun Jinling Dong Shaoyu Hao Shaoyu Hao Wei Huang The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review Frontiers in Oncology esophageal cancer neoadjuvant chemoradiotherapy neoadjuvant immunotherapy pathological complete remission (pCR) target volume delineation |
| title | The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review |
| title_full | The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review |
| title_fullStr | The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review |
| title_full_unstemmed | The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review |
| title_short | The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review |
| title_sort | key clinical questions of neoadjuvant chemoradiotherapy for resectable esophageal cancer a review |
| topic | esophageal cancer neoadjuvant chemoradiotherapy neoadjuvant immunotherapy pathological complete remission (pCR) target volume delineation |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.890688/full |
| work_keys_str_mv | AT danhan thekeyclinicalquestionsofneoadjuvantchemoradiotherapyforresectableesophagealcancerareview AT danhan thekeyclinicalquestionsofneoadjuvantchemoradiotherapyforresectableesophagealcancerareview AT baoshengli thekeyclinicalquestionsofneoadjuvantchemoradiotherapyforresectableesophagealcancerareview AT qianzhao thekeyclinicalquestionsofneoadjuvantchemoradiotherapyforresectableesophagealcancerareview AT hongfusun thekeyclinicalquestionsofneoadjuvantchemoradiotherapyforresectableesophagealcancerareview AT jinlingdong thekeyclinicalquestionsofneoadjuvantchemoradiotherapyforresectableesophagealcancerareview AT shaoyuhao thekeyclinicalquestionsofneoadjuvantchemoradiotherapyforresectableesophagealcancerareview AT shaoyuhao thekeyclinicalquestionsofneoadjuvantchemoradiotherapyforresectableesophagealcancerareview AT weihuang thekeyclinicalquestionsofneoadjuvantchemoradiotherapyforresectableesophagealcancerareview AT danhan keyclinicalquestionsofneoadjuvantchemoradiotherapyforresectableesophagealcancerareview AT danhan keyclinicalquestionsofneoadjuvantchemoradiotherapyforresectableesophagealcancerareview AT baoshengli keyclinicalquestionsofneoadjuvantchemoradiotherapyforresectableesophagealcancerareview AT qianzhao keyclinicalquestionsofneoadjuvantchemoradiotherapyforresectableesophagealcancerareview AT hongfusun keyclinicalquestionsofneoadjuvantchemoradiotherapyforresectableesophagealcancerareview AT jinlingdong keyclinicalquestionsofneoadjuvantchemoradiotherapyforresectableesophagealcancerareview AT shaoyuhao keyclinicalquestionsofneoadjuvantchemoradiotherapyforresectableesophagealcancerareview AT shaoyuhao keyclinicalquestionsofneoadjuvantchemoradiotherapyforresectableesophagealcancerareview AT weihuang keyclinicalquestionsofneoadjuvantchemoradiotherapyforresectableesophagealcancerareview |